Discussing possible JAK-inhibition, Down syndrome link with Emma Guttman-Yassky, MD, PhD
Release Date: 10/01/2025
Exploring the connections between skin, cardiovascular disorders with Brittany Weber, MD, PhD
Beneath the Surface
In this episode, guest Brittany Weber, MD, PhD, FACC, FASNC, discusses the role inflammatory diseases have on cardiometabolic disorders, evaluating patients with inflammatory disease for cardiovascular risks and more. • Intro 0:28 • Brittany Weber, MD, PhD, FACC, FASNC 0:39 • Why has the role of inflammatory diseases in cardiovascular conditions become the focus of your clinical work and research? 1:07 • Can you tell us about your recent study on cardiovascular complications in women with psoriasis who are giving birth?...
info_outline
Discussing possible JAK-inhibition, Down syndrome link with Emma Guttman-Yassky, MD, PhD
Beneath the Surface
In this episode, guest Emma Guttman-Yassky, MD, PhD, discusses inflammatory diseases, the association between JAK inhibition and Down syndrome comorbidities and more. • Intro 0:26 • Emma Guttman-Yassky, MD, PhD 0:33 • What is your new research in alopecia areata about, and what dermatologists should know about using dupilumab (Dupixent; Regeneron, Sanofi) in children with alopecia areata? 1:06 • Have you tried any other drugs to target IL-13? 3:21 • Do you think any of the currently available IL-13 targeting...
info_outline
A deep dive into iPledge changes with John Barbieri, MD
Beneath the Surface
In this episode, guest John Barbieri, MD, MBA, discusses the FDA’s 2023 proposed changes to the iPledge system and the impacts of clinical trials and treatments on patients with hormonal acne. • Intro 0:28 • John Barbieri, MD, MBA 0:42 • What does it mean to have a conditional recommendation, and why is this considered “controversial”? 1:50 • What are the reasons, such as limitations of use, that lead to a conditional recommendation? 2:48 • How would you implement these care guidelines into clinical...
info_outline
The science behind vitiligo with John Harris, MD, PhD
Beneath the Surface
In this episode, guest John E. Harris, MD, PhD, discusses how vitiligo occurs and how dermatologists can navigate the vitiligo treatment landscape. • Intro 0:28 • John E. Harris, MD, PhD 0:41 • How does vitiligo occur, and what is the basic science behind it? 1:08 • Are there any known triggers of this condition in people who have genetic susceptibility to it? 3:19 • How does drug-induced vitiligo occur in people? 4:42 • When you see a patient with vitiligo, how do you approach the...
info_outline
Exploring sodium’s effect on dermatologic disease with Katrina Abuabara, MD
Beneath the Surface
In this episode, guest Katrina Abuabara, MD, discusses the possible role of sodium in dermatologic diseases and how dermatologists can make recommendations for patients’ sodium intake. • Intro 0:29 • Katrina Abuabara, MD, MA, MSCE 0:41 • What made you think about the question behind your paper on ? 1:08 • How do you measure sodium in the skin? 2:49 • In which dermatologic diseases are abnormal sodium in the skin playing a significant role? 3:36 • Is there any evidence that changing...
info_outline
Addressing JAK inhibitor safety in alopecia with Brett King, MD, PhD
Beneath the Surface
In this episode, guest Brett King, MD, PhD, discusses the efficacy of Janus kinase (JAK) inhibitors for the treatment of alopecia areata and conversations with patients surrounding medical pauses. • Intro 0:29 • Brett King, MD, PhD 0:41 • When a patient comes to the office with alopecia areata and want to go on a JAK inhibitor, how do you counsel them about their likelihood for significant hair regrowth? 1:35 • Is your estimate of roughly fifty percent rate from data, or from your own experiences with patients? 6:03 •...
info_outline
How to embrace AI responsibly with Roxana Daneshjou, MD, PhD
Beneath the Surface
In this episode, guest Roxana Daneshjou, MD, PhD, discusses the role of artificial intelligence in dermatology practice, and the future of AI models in medicine. • Intro 0:29 • Roxana Daneshjou, MD, PhD 0:45 • What is artificial intelligence? 1:10 • What led to this largely academic endeavor becoming deployable? 2:36 • How is AI being deployed in health care today? 5:36 • What is currently deployable about AI in the dermatology space? 7:56 • How long do you think it will be...
info_outlineIn this episode, guest Emma Guttman-Yassky, MD, PhD, discusses inflammatory diseases, the association between JAK inhibition and Down syndrome comorbidities and more.
• Intro 0:26
• Emma Guttman-Yassky, MD, PhD 0:33
• What is your new research in alopecia areata about, and what dermatologists should know about using dupilumab (Dupixent; Regeneron, Sanofi) in children with alopecia areata? 1:06
• Have you tried any other drugs to target IL-13? 3:21
• Do you think any of the currently available IL-13 targeting drugs would be useful in this setting, or do you need IL-4 targeting drugs as well? 4:22
• Can you give some insight on the work you are doing surrounding the association between JAK inhibitors and patients with Down syndrome? 5:20
• Do you think that the type of psoriasis we see in patients with Down syndrome may be amenable to JAK inhibitors? 6:35
• What are some of your top tips for people who are or want to be leaders in this specialty in order to be successful? 7:53
• Thank you, Dr. Guttman. 9:41
Emma Guttman-Yassky, MD, PhD, is the Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology and director of the Center of Excellence in Eczema and the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai as well as a member of the Healio Allergy/Asthma Peer Perspective Board.
We’d love to hear from you! Send your comments/questions to Dr. Gelfand at podcasts@healio.com. Follow Dr. Gelfand on LinkedIn.
For more, be sure to visit the Beneath the Surface video blog on Healio.com.
Disclosures: Gelfand reports no relevant financial disclosures. Guttman-Yassky reports having financial relationships with AbbVie, Almirall, Amgen, AnaptysBio, Arena, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Innovaderm, Janssen Biotech, Kyowa Kirin, LEO Pharma, Novartis, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB and Ventyx Biosciences.